Home › Linfoma di Burkitt › Pennsylvania
Studi clinici su Linfoma di Burkitt nello stato di Pennsylvania
18 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Pennsylvania.
Città nello stato di Pennsylvania
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Penn State Children's Hospital, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- e altri 2
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- e altri 1
In reclutamentoFase 3
Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693Blinatumomab Consolidation in Real World
- University of Pennsylvania, Philadelphia
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoStudio osservazionale
Età da 0 a 38 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e altri 2
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Penn State Hershey Medical Center, Hershey
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Children's Hospital of Philadelphia (Data Collection Only), Philadelphia
In reclutamentoFase 3
Età 1 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
In reclutamentoFase 1/2
6 Months – 25 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1
Età da 0 a 18 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06173518A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e altri 3
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e altri 3
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 2
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- UPMC Hillman Cancer Center, Pittsburgh
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 lug 2026 · NCT07069699CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
In reclutamento
Fino a 25 anni · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT03810196Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1/2
Età da 0 a 29 · Tutti i sessi · Aggiornato il 26 mag 2026 · NCT05480449Co-administration of CART22-65s and huCART19 for B-ALL
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1/2
Fino a 29 anni · Tutti i sessi · Aggiornato il 27 mar 2026 · NCT05674175Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1/2
Età da 15 a 50 · Tutti i sessi · Aggiornato il 9 set 2025 · NCT04150497Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
In reclutamentoFase 2
Età da 18 a 79 · Tutti i sessi · Aggiornato il 13 gen 2025 · NCT05281809Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.